Abstract
Human Gene TherapyVol. 34, No. 11-12 Gene Therapy BriefsFood and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene TherapyAlex PhilippidisAlex Philippidis*Correspondence: E-mail Address: aphilippidis@liebertpub.comMary Ann Liebert, Inc., Publishers, New Rochelle, New York, USA.Search for more papers by this authorPublished Online:16 Jun 2023https://doi.org/10.1089/hum.2023.29243.bfsAboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetails Volume 34Issue 11-12Jun 2023 InformationCopyright 2023, by Mary Ann Liebert, Inc., publishersTo cite this article:Alex Philippidis.Food and Drug Administration Sets Stage for Approval of First Duchenne Muscular Dystrophy Gene Therapy.Human Gene Therapy.Jun 2023.477-480.http://doi.org/10.1089/hum.2023.29243.bfsPublished in Volume: 34 Issue 11-12: June 16, 2023PDF download
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
